Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects.
about
A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsyDiverse mechanisms of antiepileptic drugs in the development pipelineUpdate on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsyAn Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic DrugsRole of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures.Therapeutic Drug Monitoring of the Newer Anti-Epilepsy MedicationsPharmacokinetics and drug interactions of eslicarbazepine acetate.Update on treatment of partial onset epilepsy: role of eslicarbazepinePractice Update: Review of Anticonvulsant Therapy.Eslicarbazepine acetate (BIA 2-093).New antiepileptic drugs that are second generation to existing antiepileptic drugs.Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.New and investigational antiepileptic drugs.Novel medications for epilepsy.Eslicarbazepine acetate for partial-onset seizures.Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures.Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy.Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures.The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.Eslicarbazepine acetate for the treatment of partial epilepsy.Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures.Development and Validation of an RP-HPLC Method for Quantitative Estimation of Eslicarbazepine Acetate in Bulk Drug and Tablets.Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers.Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers.Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy.Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases.Interactions between cannabidiol and commonly used antiepileptic drugs.Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy.A Pharmacokinetic Study Comparing Eslicarbazepine Acetate Administered Orally as a Crushed or Intact Tablet in Healthy Volunteers.Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’.Eslicarbazepine acetate: a new option for the treatment of focal epilepsyEvaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc StudyEslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures
P2860
Q24621327-BC78D7C8-54A1-4C2C-AB51-3D444A523DD7Q24675330-5E70DB23-6C5B-41DF-B5A1-13945F38F05CQ26745780-E2C9A054-0499-4F8C-ABDC-40DCAB195E2CQ28069989-FFFB1D35-3081-495E-85DF-C3526F2CBDB7Q33802172-37CC39D3-712D-45D9-91A5-748092C57B4DQ33996679-91F8BCE9-73A9-4AA9-9C60-44336F63B44EQ34276263-1241D708-4AEC-41DE-A4DE-FA2325FB54E5Q34329823-872A26F7-B5EA-41E7-8F4B-A982B95958DAQ34518509-34F2A6C4-4A83-4FBC-93BA-B93C0DA84627Q34596785-B3FC5269-EBA9-4D13-92EA-AB99DD23BC9EQ36491829-999D5085-F0A9-4016-9B65-4686F6C44871Q36947574-BD0091B6-FE2C-4474-A968-541BE83354F8Q37638688-EBA15FDA-00A1-4E0D-AC55-BDA2086C6ADAQ37950518-4ABC5BD6-9887-40B8-82D6-D6B1E1F7623CQ37957121-608FDF7B-7557-42D9-9098-3DF144A861F0Q37992162-C89EC4E8-942F-4D91-B0B6-221BB2E90747Q38223958-CBCCC476-5ABE-4F1A-91C3-9C5F7D69FCA9Q38367761-43C9C885-6EA2-4EA4-A948-3EC13A870464Q38537865-CC5769AB-2A8B-494B-9BCA-C8CB112EC472Q38542064-3E5B2379-3785-4BBE-B75D-2B3B4A3AE3E4Q38621010-B00F4B92-508B-4792-9642-C6DA88595F3FQ38826584-BF31831D-18E2-4B12-BC35-A3606FE0AB64Q39456360-95C56B73-5267-414C-A793-4A53D1AC0EB1Q41964930-9B6B3F9B-2C9C-48D7-961B-F62DFA384692Q44062629-6FF02F31-26C2-41A0-BA05-DDC99912493EQ46265751-5CC9EB70-1C3A-42F3-AE4F-0170EACFDE84Q46570612-E591DB24-9B7F-4F9C-A2A1-851036FEEFBEQ48214354-51343133-4167-4158-9FA8-A0A0CA463A1DQ48283873-EFDFBEEC-5695-426D-B102-BA2B6104F51CQ51736900-4B6E46AD-10CB-460B-9817-C50288FA94F0Q53156110-81D2CC87-3D35-4379-8317-4D0A1CBAFDA4Q55221688-9B6B6A62-B7D5-4111-A3F0-686CF065EF20Q58870328-A0836D76-C2D3-4371-BDB7-CDF994477E88Q59284818-69AA72C8-371B-4FD5-9A9E-40A107C383D3Q59284846-37FF31C3-7EBF-4E12-A913-E35598243207
P2860
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Single-dose and steady-state p ...... hy elderly and young subjects.
@en
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate
@nl
type
label
Single-dose and steady-state p ...... hy elderly and young subjects.
@en
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate
@nl
prefLabel
Single-dose and steady-state p ...... hy elderly and young subjects.
@en
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate
@nl
P2093
P2860
P50
P356
P1476
Single-dose and steady-state p ...... hy elderly and young subjects.
@en
P2093
Dago Mazur
Joana Maia
Manfred Gellert
P2860
P304
P356
10.1177/0091270005279364
P577
2005-09-01T00:00:00Z